Introduction {#Sec1}
============

Voltage-gated Ca^2+^ channels (VGCCs) control membrane excitability, gene expression, and neurotransmitter release \[[@CR1]\]. Alterations in these cellular functions occur when GPCR-activated signal transduction cascades modulate VGCCs. In medium spiny neurons (MSNs) of the striatum, GPCRs, including M~1~Rs and D~2~Rs, inhibit VGCC activity \[[@CR2], [@CR3]\]. These GPCRs specifically inhibit Ca~V~1.3 L-current, decreasing the output of MSNs \[[@CR3], [@CR4]\] and may have functional consequences for motor control \[[@CR5], [@CR6]\].

Although present in MSNs, M~1~R signaling has been characterized most thoroughly in superior cervical ganglion (SCG) neurons. M~1~Rs couple to Gα~q~ and phospholipase C (PLC) to inhibit native L- and N-VGCC currents \[[@CR7]--[@CR9]\]. This signal transduction cascade, referred to as the slow or diffusible second messenger pathway, is characterized as pertussis toxin (PTX)-insensitive, voltage-independent, and requiring intracellular Ca^2+^ to function \[[@CR10]\]. Our laboratory has identified arachidonic acid (AA) as a critical effector in the slow pathway \[[@CR9]\]. Exogenously applied AA inhibits L-current \[[@CR11]--[@CR13]\], which in SCG neurons most likely arises from Ca~V~1.3 \[[@CR14]\]. Moreover, Ca^2+^-dependent cytosolic phospholipase A~2~ (cPLA~2~) appears critical for release of AA from phospholipids following M~1~R activation; loss of cPLA~2~ activity by pharmacological antagonists or gene knockout ablates L-current inhibition \[[@CR15], [@CR16]\].

Additionally, D~2~Rs inhibit L-current via a diffusible second messenger pathway involving phospholipase C (PLC), InsP~3~, and calcineurin in MSNs \[[@CR3]\]. While both GPCRs signal through PLC, they share another commonality: their activation releases AA from striatal neurons \[[@CR17], [@CR18]\] and transfected cell lines \[[@CR19], [@CR20]\]. Therefore, D~2~Rs may also inhibit L- (Ca~V~1.3) and N-(Ca~V~2.2) currents via a pathway utilizing cPLA~2~ to release AA. In the present study, we tested whether the M~1~R and D~2~R pathways converge to modulate recombinant L-VGCC activity.

Main text {#Sec2}
=========

Materials and methods {#Sec3}
---------------------

### Cell culture {#Sec4}

Human embryonic kidney cells, stably transfected with the M1 muscarinic receptor (HEK-M1) \[a generous gift from Emily Liman, University of Southern California, originally transfected by \[[@CR21]\] \] were propagated at 37 °C with 5% CO~2~ in Dulbecco's MEM (DMEM)/F12 supplemented with 10% FBS, 1% G418, 0.1% gentamicin, and 1% HT supplement (Gibco Life Technologies). Cells were passaged when 80% confluent.

### Transfection {#Sec5}

HEK-M1 cells, grown in 12-well plates (\~ 60--80% confluent), were transfected with a 1:1:1 molar ratio of Ca~V~1.3b or Ca~V~2.2, α~2~δ-1 and different Ca~V~βs \[[@CR22]\], using Lipofectamine PLUS (Invitrogen) according to the manufacturer's instructions. Cells were co-transfected with green fluorescent protein (GFP) to identify transfected cells. Constructs for Ca~V~1.3b (+exon11, Δexon32, +exon42a; GenBank accession \#AF370009), Ca~V~2.2 (^a^10, Δexon18a, Δexon24a, +exon31a, +exon37b, +exon46; \#AF055477), Ca~V~β~3~ (\#M88751) and α~2~δ-1 (\#AF286488) were provided by Diane Lipscombe (Brown University). Ca~V~β~1b~ (\#X61394), Ca~V~β~2a~ (\#M80545), and Ca~V~β~4~ (\#L02315) constructs were provided by Edward Perez-Reyes (University of Virginia). The D~4.4~R (\#AF1199329) construct was provided by Hubert H. M. Van Tol (University of Toronto). D~2~R cDNA (\#NM_000795) was obtained from the UMR cDNA Resource Center (<https://www.cdna.org>). Per well, a total of 0.5 μg of DNA (of which GFP cDNA was less than 10%) was used following the methods of Roberts-Crowley and Rittenhouse (2009) \[[@CR13]\].

### Electrophysiology {#Sec6}

Whole-cell currents were recorded following the methods of Liu et al. \[[@CR11]\]. High resistance seals were established in Mg^2+^ Tyrode's (in mM): 5 MgCl~2~, 145 NaCl, 5.4 KCl, and 10 HEPES, brought to pH 7.50 with NaOH. Once a seal was established and the membrane ruptured, the Tyrode's solution was exchanged for external bath solution (in mM): 125 NMG-aspartate, 20 Ba-acetate, 10 HEPES, brought to pH 7.50 with CsOH. Only cells with ≥ 0.2 nA of current were used. Data were acquired using Signal 2.14 software (CED) and stored for later analysis on a personal computer. Linear leak and capacitive currents were subtracted from all traces.

### Drugs {#Sec7}

All chemicals were purchased from Sigma unless otherwise noted. FPL 64176 (FPL), nimodipine (NIM), and oleoyloxyethyl phosphorylcholine (OPC, Calbiochem) were prepared as stock solutions in 100% ethanol. Quinpirole (quin) and Oxotremorine-M (Oxo-M, Tocris) were dissolved in DDW and stored as 10 mM stock solutions at − 70 °C. Stocks were diluted daily to the final concentration by at least 1000-fold with external solution. For ethanol-prepared stocks, the final ethanol concentration was less than 0.1%.

### Statistical analysis {#Sec8}

Data are presented as the mean ± s.e.m. Data were analyzed for significance using a Student's paired *t*-test for two means, or a one-way ANOVA followed by a Tukey multiple-comparison post hoc test. Statistical significance was set at *p *\< 0.05 or \< 0.001. Analysis programs included Signal (CED), Excel (Microsoft), and Origin (OriginLab).

Results {#Sec9}
-------

### Characterization of recombinant Ca~V~1.3 current as L-type in HEK-M1 cells {#Sec10}

Whole-cell L-currents, from β~3~-containing L-channels, elicited from a holding potential of − 60 mV to a test potential of − 10 mV, averaged − 4699 ± 279 pA (n = 3) compared to − 9 ± 1 pA for HEK-M1 cells transfected with only accessory subunits (n = 10, *P *\< 0.001). Lack of current from cells transfected without Ca~V~1.3b, confirmed that HEK-M1 cells exhibit little endogenous Ca^2+^ current and transfection of accessory subunits does not upregulate endogenous Ca^2+^ channels. Recombinant current was confirmed as L-type by showing sensitivity to the L-VGCC antagonist NIM. NIM inhibited β~3~-containing currents (Additional file [1](#MOESM1){ref-type="media"}A) in a concentration-dependent manner (Additional file [1](#MOESM1){ref-type="media"}B). Currents were also sensitive to FPL, which enhanced current from β~2a~- and β~3~-containing channels and produced long-lasting tail currents upon repolarization (Additional file [1](#MOESM1){ref-type="media"}C, D). Additionally, FPL produced a slight hyperpolarizing voltage shift in the peak inward current and enhanced current amplitude at all voltages (Additional file [1](#MOESM1){ref-type="media"}E). Additional file [1](#MOESM1){ref-type="media"}F demonstrates that FPL enhanced the long-lasting tail current in a concentration-dependent manner. These pharmacological and biophysical properties show that transfection of HEK-M1 cells with Ca~V~1.3b and accessory subunits produce currents with L-type characteristics.

### The Ca~V~β-subunit varies the magnitude of Ca~V~1.3 current inhibition by M~1~Rs {#Sec11}

In MSNs, M~1~R stimulation inhibits L-current in Ca~V~1.2 knockout animals \[[@CR4]\]. Only Ca~V~1.2 and Ca~V~1.3 constitute the L-type Ca~V~α~1~ subunits expressed in brain \[[@CR23]\], implying that M~1~Rs specifically inhibit Ca~V~1.3 current. Using a cell line transfected with only Ca~V~1.3 channels provides molecular proof for the identity of the inhibited channel. Therefore, to determine if activation of M~1~Rs inhibits Ca~V~1.3 activity, peak current amplitudes were measured prior to and following application of the M~1~R agonist Oxo-M. Figure [1](#Fig1){ref-type="fig"}a compares representative current traces for Ca~V~1.3b coexpressed with β~1b~, β~2a~, β~3~, or β~4~-subunits in the absence or presence of Oxo-M. After 1 min, Oxo-M significantly inhibited L-current by 58 ± 8% with β~1b~; 36 ± 12% with β~2a~; 66 ± 6% with β~3~; and 72 ± 10% with β~4~ (Fig. [1](#Fig1){ref-type="fig"}c). Oxo-M elicited kinetic changes that were visualized by normalizing individual traces to the end of the 40 ms test pulse (Fig. [1](#Fig1){ref-type="fig"}b), which were quantified by measuring TTP and *r*40 (Fig. [1](#Fig1){ref-type="fig"}d). TTP (Fig. [1](#Fig1){ref-type="fig"}e) and *r*40 (Fig. [1](#Fig1){ref-type="fig"}f) decreased following Oxo-M with β~1b~, β~3~, or β~4~; however, no changes were detected with β~2a~ (*P *≥ 0.11 for TTP; *P *≥ 0.40 for *r*40). These differences in the magnitude of current inhibition and kinetics suggest that the Ca~V~β-subunit affects M~1~R modulation of Ca~V~1.3b.Fig. 1Ca~V~1.3b current inhibition and kinetic changes produced by M~1~R stimulation are Ca~V~β-subunit dependent. **a** Representative current traces from Ca~V~1.3b coexpressed with β~1b~, β~2a~, β~3~ or β~4~ before (black) or 1 min after applying 10 μM Oxo-M (red). **b** Current traces from **a** were normalized to the end of the test pulse. **c** Summary of Oxo-M inhibition of Ca~V~1.3b with different Ca~V~β-subunits. Maximal inward current amplitudes were measured after the onset of the test pulse using a trough seeking function (peak current). Percent of current inhibition was calculated as: *%I*~*inhib*~= *100\*(I*~*CTL*~--*I*~*DRUG*~*)∕I*~*CTL*~ , where I~CTL~ and I~DRUG~ are the average maximum current amplitude of 5 traces prior to and after 1 min of application of test material (unless otherwise noted). **d** Schematic of quantification of kinetic changes. **e**, **f** Summary of kinetic changes (n = 4--6, \*\*\**P *\< 0.001, \*\**P *\< 0.05) open bars, control; hatched bars, Oxo-M. **e** Time to peak (TTP) was measured using a minimum seeking function in Signal within the test pulse duration. **f** Current remaining (*r*40) was measured from an average of five normalized current traces per condition using the equation: *r40 *= *100\*I*~*end*~*∕I*~*peak*~ , where *r*40 is the percent of the maximum inward current remaining at the end of a 40 ms test pulse; I~end~ is the current amplitude at the end of the test pulse; I~peak~ is the maximum inward current measured during the test pulse

### Dopamine D~2~ receptors inhibit Ca~V~2.2 but not Ca~V~1.3 currents {#Sec12}

Both M~1~Rs and D~2~Rs activate pathways involving G proteins, PLC, and AA release (Fig. [2](#Fig2){ref-type="fig"}a). However, whether L-current inhibition by D~2~Rs shows varied inhibition depending on Ca~V~β-subunit expression has not been examined. Therefore, we coexpressed D~2~Rs with Ca~V~1.3b, α~2~δ-1 and different Ca~V~β-subunits. While Oxo-M inhibited Ca~V~1.3b-β~2a~ currents over time (Fig. [2](#Fig2){ref-type="fig"}b), quin, a D~2~R agonist, had no effect on current amplitude (Fig. [2](#Fig2){ref-type="fig"}c) or kinetics (Fig. [2](#Fig2){ref-type="fig"}c inset, g). Since Ca~V~1.3b-β~2a~ current shows less inhibition and no kinetic changes with Oxo-M, we tested whether Ca~V~1.3b-β~3~ current was sensitive to modulation by quin. Figure [2](#Fig2){ref-type="fig"}d shows a time course of Ca~V~1.3b-β~3~ current inhibition by Oxo-M whereas the time course with quin (Fig. [2](#Fig2){ref-type="fig"}e) shows no inhibition or kinetic change (Fig. [2](#Fig2){ref-type="fig"}e inset, g). Several concentrations of quin were tested but did not inhibit L-current to the same extent as Oxo-M (Fig. [2](#Fig2){ref-type="fig"}f). D~2~Rs appeared to desensitize with 10 μM quin. Application of quin for 1 min to cells co-transfected with the D~2~R-like family member, D~4.4~R, inhibited L-current by 8.5 ± 2.5% and did not produce changes in TTP or *r*40 (Additional file [2](#MOESM2){ref-type="media"}).Fig. 2M~1~Rs but not D~2~Rs inhibit recombinant L-current. **a** Comparison of M~1~R and D~2~R signaling pathways that inhibit L-VGCC activity. **b** Time course of Oxo-M applied at time 0 for Ca~V~1.3b-β~2a~ current. **c** Time course of 10 nM quin applied at time 0 for Ca~V~1.3b-β~2a~ current. Inset: (*left*) Individual current traces before (black) and after 1 min of quin, scale bar = 0.5 nA. (*right*) Normalized traces. **d** Time course of Oxo-M applied at time 0 for Ca~V~1.3b-β~3~ current. **e** Time course of 0.5 μM quin applied at time 0 for Ca~V~1.3b-β~3~ current. Inset: same as **c**, scale bar = 1 nA. **f** Concentration--response curve of quin on Ca~V~1.3b-β~2a~ (filled circles) and Ca~V~1.3b-β~3~ (open circles) currents (n = 2--5). **g** Summary of kinetic analysis

To confirm that lack of L-current inhibition was not due to poor expression of D~2~Rs, we repeated the experiment but substituted Ca~V~2.2 for Ca~V~1.3b to serve as a positive control since activated D~2~Rs also inhibit Ca~V~2.2 \[[@CR24]--[@CR26]\]. Quin inhibited Ca~V~2.2 by 45 ± 7% after 30 s and 48 ± 4% after 1 min (Fig. [3](#Fig3){ref-type="fig"}a). Inhibition occurred specifically by activating transfected D~2~Rs because cells transfected without D~2~Rs showed no response to quin (Fig. [3](#Fig3){ref-type="fig"}a, n = 3). Moreover, N-current inhibition by quin occurred in a concentration-dependent manner (Fig. [3](#Fig3){ref-type="fig"}b, n = 3--5). Compared to lower concentrations, 10 μM quin resulted in less inhibition; inhibited current did not recover upon wash, suggesting this concentration causes receptor desensitization (data not shown). Thus, our findings indicate that transfected D~2~Rs functionally express in HEK-M1 cells to modulate Ca~V~2.2, but not Ca~V~1.3b VGCC activity.Fig. 3D~2~Rs and M~1~Rs inhibit recombinant N-current demonstrating successful expression of both GPCRs. To demonstrate that D~2~Rs are functional, HEK-M1 cells were transfected with the D~2~R, Ca~V~2.2, α~2~δ~1~, and a Ca~V~β subunit plasmids using the same conditions as described in the Methods section and in Additional file [1](#MOESM1){ref-type="media"} legend as described for Ca~V~1.3b. **a** Time course of Ca~V~2.2-β~3~ current inhibition by 0.5 μM quin added at time 0 with (filled circles, n = 8, *P *\< 0.001 compared to CTL) or without (open circles, n = 3) co-transfection of D~2~Rs. **b** Concentration--response curve of quin on Ca~V~2.2-β~3~ current (n = 3--5). **c** Time course of Ca~V~2.2-β~3~ current inhibition by Oxo-M added at time 0 under CTL conditions (filled circles, n = 5, *P *\< 0.001 compared to CTL) or preincubation for at least 3 min with 10 μM of the PLA~2~ antagonist, OPC (open circles, n = 5, *P *\< 0.05 compared to Oxo-M alone, ANOVA). **d** Time course of Ca~V~2.2-β~3~ current inhibition by 10 (filled triangles) or 50 nM (filled circles) quin under control conditions or preincubated with OPC (open symbols) (n = 1--5). **e** Representative Ca~V~2.2-β~2a~ currents measured at a test potential of + 20 mV (−PP) from a holding potential of − 90 mV. A 25 ms prepulse to + 120 mV was placed before a second test pulse (+PP) to measure for membrane-delimited inhibition. CTL current (black) or 30 s after application of 0.5 μM quin (grey). **f** Same as **e** in the presence of 1 mg/ml BSA. **g** Time course of Ca~V~2.2-β~2a~ current (−PP, filled circles; +PP, open circles) exposed to 0.5 μM quin at time 0 for 1 min. After washing, current fully recovered; BSA was added for 3 min before addition of BSA/quin. **h** Summary of Ca~V~2.2-β~2a~ inhibition by quin (n = 9) or BSA/quin (n = 3)

### M~1~R and D~2~R pathways use different signaling mechanisms to inhibit N-current {#Sec13}

To compare D~2~Rs and M~1~Rs signaling pathways on Ca~V~2.2 current, we first confirmed that activation of the stably transfected M~1~Rs could suppress N-current. Indeed, Oxo-M inhibited currents from β~3~-containing channels by 70 ± 5% after 30 s (Fig. [3](#Fig3){ref-type="fig"}c). When incubated with the PLA~2~ antagonist OPC, cells showed less N-current inhibition by Oxo-M, 14 ± 8% inhibition after 30 s (Fig. [3](#Fig3){ref-type="fig"}c). In contrast, low concentrations of quin still suppressed N-current in the presence of OPC (Fig. [3](#Fig3){ref-type="fig"}d). Inhibition was relieved by pre-pulse facilitation (Fig. [3](#Fig3){ref-type="fig"}e, g, h) and occurred in the presence of BSA, which acts as a scavenger of free AA (Fig. [3](#Fig3){ref-type="fig"}f--h), suggesting that quin mediates membrane-delimited inhibition of N-current. These findings suggest that M~1~Rs and D~2~Rs do not share a common pathway leading to N-current inhibition.

Discussion {#Sec14}
----------

Previously, the Ca~V~1.3b splice variant of L-VGCCs, found in MSNs, had not been specifically tested for modulation by GPCRs. Here, using HEK-M1 cells, we present the novel finding that M~1~R stimulation inhibits Ca~V~1.3b L-current with the accessory Ca~V~β-subunit determining the magnitude of inhibition. In contrast, stimulation of transfected D~2~Rs with quin does not recapitulate L-current inhibition observed in MSNs \[[@CR3]\]. Pharmacological sensitivity to both FPL and NIM confirmed that Ca~V~1.3b expressed in HEK-M1 cells behaves similarly to other recombinant Ca~V~1.3 VGCCs \[[@CR22], [@CR27]\].

We also report that N-current modulation by the D~2~R short splice variant appears similar to membrane-delimited inhibition by the D~2~R long form \[[@CR24]\]. In this form of modulation, when G proteins are activated, Gβγ directly binds to and inhibits Ca~V~2.2 which can be reversed by strong prepulses \[[@CR10], [@CR28]\]. Indeed, D~2~R-mediated inhibition of Ca~V~2.2 was independent of PLA~2~, whereas blockers of PLA~2~ abolished inhibition by M~1~Rs. Thus, the membrane-delimited pathway may be at least partially responsible for the inhibition of Ca~V~2.2 by D~2~Rs in MSNs \[[@CR25]\].

In our experiments, the short splice variant of Ca~V~1.3 (Ca~V~1.3b) was unaffected by activation of D~2~Rs, expressed in HEK-293 cells, similar to a previous report on Ca~V~1.3a, which has a longer C-terminus \[[@CR24]\]. Since neither D~2~R-long inhibited Ca~V~1.3a \[[@CR24]\], nor D~2~R-short inhibited Ca~V~1.3b (Fig. [2](#Fig2){ref-type="fig"}f), one possibility is that another channel/receptor combination occurs in vivo; however, D~2~R-long and short equally couple to G~i~ proteins \[[@CR29]\]. On the other hand, Ca~V~1.3a binds a scaffolding protein found in the postsynaptic density of synapses known as Shank \[[@CR30]\]. In MSNs, Ca~V~1.3a requires an association with Shank for current inhibition by D~2~Rs \[[@CR4]\]. Although lack of the longer Ca~V~1.3 C-terminus may explain the absence of channel modulation by D~2~Rs in our studies, we found that Oxo-M inhibits Ca~V~1.3b currents, showing that this short splice variant of Ca~V~1.3 can be modulated by a G~q~PCR. Therefore, a missing intermediary protein vital for D~2~R modulation of Ca~V~1.3b may underlie the lack of inhibition reported here, or D~2~Rs may not modulate Ca~V~1.3b.

Conclusions {#Sec15}
-----------

These findings highlight the specific regulation of Ca^2+^ channels in a Ca~V~β-subunit dependent manner by different neurotransmitters. While M~1~R and D~2~R pathways contain similar signaling molecules and share a common functional output of inhibiting Ca^2+^ channels, differences between the two cascades exist. Expression and localization of Ca~V~1.3b associated with different Ca~V~β-subunits in a tissue or cell may dictate how Ca^2+^ influx is modulated by nearby GPCRs, ultimately affecting Ca^2+^-dependent processes.

Limitations {#Sec16}
===========

Further experiments are needed to determine the differences in signaling between successful Ca~V~1.3b inhibition by M~1~Rs versus none with D~2~Rs.

Additional files
================

 {#Sec17}

**Additional file 1.** Pharmacological characterization of Ca~V~1.3b L-current. HEK-M1 cells were washed with DMEM and the DNA mixture of Ca~V~1.3b, α~2~δ-1, a β~3~-subunit and GFP was added and incubated for 1 h at 37 °C in a 5% CO~2~ incubator. Supplemented media, without antibiotics, was then returned to the cells to bring the volume up to 1 ml (normal medium volume). After 2 h, cells were washed with supplemented media and washed a final time 2 h later. 10 mM MgSO~4~ was added to the medium to block basal activity of Ca~V~1.3b, which helped minimize excitotoxicity of transfected cells. Cells were transferred 24--72 h post-transfection using 2 mM EDTA in 1X PBS, to poly-*[l]{.smallcaps}*-lysine-coated coverslips. Recording began 1 h after transfer to coverslips. **A** Individual traces of Ca~V~1.3b-β~3~ current before (CTL) and after exposure to 0.3 µM NIM. **B** Concentration--response curve of L-current inhibition to NIM (n = 4--8). **C** Ca~V~1.3b-β~2a~ currents before and after exposure to FPL (1 µM). Cells were stepped to a test potential of − 10 mV from a holding potential of − 90 mV followed by repolarization to − 90 or − 50 mV. Control (CTL) currents from β~2a~-containing L-VGCCs show little to no inactivation as observed previously \[[@CR31]\]. **D** Ca~V~1.3b-β~3~ currents before and after FPL. Cells were stepped to a test potential of − 10 mV from a holding potential of − 60 mV followed by repolarization to − 60 mV. Following FPL, both β~2a~- and β~3~-containing channels exhibited slower activation and deactivation kinetics, hallmarks of agonist action on L-current \[[@CR32]\]. **E** FPL enhancement of the Ca~V~1.3b-β~2a~ current--voltage plot from a holding potential of − 90 mV (CTL, filled circles; FPL, open circles, n = 3, \**P *\< 0.05). **F** Concentration--response curve of Ca~V~1.3b-β~3~ tail current enhancement to FPL (n = 4--8). Currents inhibited by NIM and enhanced by FPL fully recovered by washing with bath solution (data not shown). **Additional file 2.** D~4.4~Rs do not inhibit recombinant L-current. **A** Summary bar graph of Ca~V~1.3b-β~3~ current inhibition by 0.5 μM quin (n = 5). **B & C** Summary bar graphs of TTP and *r*40 kinetic analysis.
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